Skip to main content

Table 1 Demographics and biochemical profile of the patient cohort used for biomarker discovery

From: Identification of potential serum peptide biomarkers of biliary tract cancer using MALDI MS profiling

 

Clinical group

 

Variable

BTC

PSC

IAC

Benign other

Healthy

Number

39

10

7

14

22

Female: male

15:24

3:7

0:7

9:5

7:15

Age (yrs)

69 (27–93)

48 (22–76)

64 (43–71)

53 (35–47)

60 (39–78)

Bilirubin (μmol/L)

40 (8–616)

17 (7–457)

12 (5–40)

8 (4–38)

ND

CA19-9 (U/mL)

295 (1–145528)

17 (1–4119)

15 (1–52)

ND

ND

CA19-9 >37 U/mL

30/39

3/10

1/4

ND

ND

CRP mg/L (N < 5)

44.4 (1–171)

9.9 (1–194.2)

8.6 (5–35.7)

ND

ND

ALP (U/L)

577 (138–1925)

195 (98–514)

229 (69–642)

ND

ND

IgG4 g/L (N < 1.3 g/L)

ND

ND

1.5 (0.49-2.57)

ND

ND

WCC (x109/L)

8.2 (3.3-14.8)

6.0 (4.3-15.0)*

7.6 (2.3-9.8)

ND

ND

Neutrophils (x109/L)

5.9 (2.3-12.0)

3.3 (2.8-13.4)*

4.1 (0.7-5.4)

ND

ND

  1. BTC, biliary tract cancer; PSC, primary sclerosing cholangitis; IAC, IgG4-associated cholangitis. Benign other group comprises sphincter of Oddi dysfunction, stenosis of the Ampulla of Vater and chronic pancreatitis. CA19-9, carbohydrate antigen 19–9; CRP, C-reactive protein; ALP, alkaline phosphatase; IgG4, immunoglobulin G4; WCC, white cell count. Unless otherwise indicated, values indicate median (with range); ND, not determined; *WCC and neutrophil counts were available for only 6 of the 11 PSC patients.
Back to article page

BMC Clinical Pathology

ISSN: 1472-6890

Contact us